The Co-CEOs of the company, Michael Frankel and Howard Schwimmer, expressed their commitment to driving long-term shareholder value and stated their focus on executing value creation strategies for the benefit of their shareholders.
$ArcBest(ARCB.US)$initiated at buy by Jefferies, announced target price at $110.00. $Saia(SAIA.US)$initiated at buy by Jefferies, announced targe price at $350.00. $汽車地帶(AZO.US)$was upgraded by Evercore ISI Group from in-line to outperform, increased target price to $2700.00. $甲骨文(ORCL.US)$was upgraded by Wolfe Research from peer perform to outperform, increased target price to $130.00. $BILL Holdings(BILL.US)$was downg...
Rexford Industrial Realty股票討論區
2023前兩季度營收增長31.8%,營業利潤增長36.9%,淨利潤增長34.2%。
目前市盈率57.7,市盈率TTM降到54.2,如果全年淨利潤增長35%,市盈率將下降到42.7,對於週期性非常強的板塊來說這個估值似乎有點太高了。
專欄US Top Rating Updates on 6/12: AZO, ORCL, BILL, KMX and More
$Saia(SAIA.US)$ initiated at buy by Jefferies, announced targe price at $350.00.
$汽車地帶(AZO.US)$ was upgraded by Evercore ISI Group from in-line to outperform, increased target price to $2700.00.
$甲骨文(ORCL.US)$ was upgraded by Wolfe Research from peer perform to outperform, increased target price to $130.00.
$BILL Holdings(BILL.US)$ was downg...
專欄Top upgrades and downgrades on 6/21: XOM, ADBE, UAA, BEKE and more
• $反導工業(ABM.US)$ : Baird Upgrades to Outperform from Neutral - PT $50
• $美國電塔(AMT.US)$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $丘奇&德懷特(CHD.US)$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $康西哥(CNC.US)$ : Credit Suisse Upgrades to Outperform from...
專欄Today's pre-market stock movers: ARRY, RIOT, MRNA, NVAX and more
• $Array Technologies(ARRY.US)$ +12.87% (also names new CEO)
• $Tufin軟件科技(TUFN.US)$ +43.41% (enters into definitive agreement to be acquired by Turn/River Capital in a $570 million transaction; TUFN shareholders will receive $13.00/share in cash)
• $Citius Pharmaceuticals(CTXR.US)$ +10.87% (reported topline results from the pivotal Phase 3 trial of I/ONTAK)
• $BioXcel Therapeutics(BTAI.US)$ +19.22% (FDA ha...
暫無評論